Please wait while the formulary information is being retrieved.
BICALUTAMIDE (BICALUTAMIDE)
- Metastatic prostate carcinoma
50 mg tablet
- 1 tablet (50 mg) by oral route once daily
50 mg tablet
- 1 tablet (50 mg) by oral route once daily
Metastatic prostate carcinoma
- 1 tablet (50 mg) by oral route once daily
- natalizumab
- Tysabri
Contraindicated
- None
Severe
Moderate
- Juxtapid
- lomitapide
- Drug-induced hepatitis
- Pregnancy
Contraindicated
- Abnormal hepatic function tests
- Disease of liver
- Interstitial pneumonitis
Severe
Moderate
- Anemia
- Diabetes mellitus
BICALUTAMIDE (BICALUTAMIDE)
- Metastatic prostate carcinoma
- Anemia
- Dyspnea
- Hypertension
- Infection
- Acute confusion
- Anorexia
- Constipation
- Diarrhea
- Dizziness
- Drowsy
- Dyspepsia
- Erectile dysfunction
- Flatulence
- Flushing
- General weakness
- Gynecomastia
- Hematuria
- Libido changes
- Mastalgia
- Myalgias
- Nausea
- Nocturia
- Pain
- Peripheral edema
- Vomiting
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Depression
- Dysuria
- Urinary retention
- Bone pain
- Flu-like symptoms
- Headache disorder
- Increased urinary frequency
- Muscle weakness
- Paresthesia
- Symptoms of anxiety
- Urinary incontinence
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Angioedema
- Chronic heart failure
- Gout
- Hepatic failure
- Hepatitis
- Hypersensitivity drug reaction
- Interstitial pneumonitis
- Jaundice
- Pulmonary fibrosis
- Rectal bleeding
- Sepsis
Less Severe
- Acute abdominal pain
- Alopecia
- Angina
- Asthma
- Black tarry stools
- Chills
- Dehydration
- Dry skin
- Dysphagia
- Edema
- Epistaxis
- Fever
- Hypercholesterolemia
- Hyperglycemia
- Hypertonia
- Neck pain
- Nervousness
- Periodontal infection
- Pruritus of skin
- Skin photosensitivity
- Syncope
- Urinary urgency
- Urticaria
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Bicalutamide
Study for central precocious puberty did not demonstrate statistical evidence for reducing growth rate. No established safety and efficacy.
- 1 Day – 18 Years
- Study for central precocious puberty did not demonstrate statistical evidence for reducing growth rate. No established safety and efficacy.
Bicalutamide
- Severity Level:
1
- Additional Notes: Not indicated for use in women, contraindicated
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Bicalutamide
Not indicated for use in women
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Not indicated for use in women |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Metastatic prostate carcinoma | |
| C61 | Malignant neoplasm of prostate |
| 0-9 | A-Z |
|---|---|
| C61 | Malignant neoplasm of prostate |
Formulary Reference Tool